Merck licenses HAPPYneuron e-health solution for MS patients

Merck has received an exclusive licence to a cognitive remediation training programme for people living with multiple sclerosis (MS) developed by HAPPYneuron.

The software-based cognitive training service consists of a series of games designed to address cognitive challenges faced by people with MS. The games automatically adjust their difficulty to match the needs of the individual.

Under the terms of the new licensing deal, the HAPPYneuron programme will be available for inclusion in Merck's MSdialog platform when deemed beneficial for a patient by the relevant healthcare provider.

Rehan Verjee, chief marketing and strategy officer of Merck's biopharma business, said: "The platform will enhance the attractiveness of MSdialog to patients and healthcare providers by seeking to address these cognitive deficit symptoms and further fostering the monitoring of the cognitive state of patients."

MSdialog is a multi-tenant cloud-based software system for the management of MS that captures and presents patient outcome data, while also helping patients manage their conditions through the use of reminders and questionnaires.

It is currently available in 24 countries, with further launches planned for Brazil, Argentina, Israel, Italy, France and the Netherlands.